Plexxikon's proprietary discovery platform enables the design of highly selective and targeted medicines, supporting the company's broader strategy to develop personalized medicines. The company has a diverse pipeline of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, oncology, and CNS, as well as inflammation and cardiovascular diseases. Plexxikon's demonstrated capability in discovery and early development, combined with an experienced management and scientific team, have been key drivers of the company's success since it began operations in 2001.